MEDTECH

Salipro Biotech Receives European Patent for Antigen production

Salipro Biotech | February 09, 2022

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform technologies for the discovery and development of next-generation therapeutics against challenging drug targets such as GPCRs, ion channels and transporters.

"We're constantly increasing our collaborations, partnerships and licensing agreements with major pharma companies on a wide range of challenging drug targets. Expanding our already strong patent portfolio further will enable us to increase the value of such collaborations for our partners as well as moving towards building our own discovery pipeline."

Maria Knudsen, Business Development Director at Salipro Biotech AB

Jens Frauenfeld, CEO, comments: "We're excited about this important milestone that provides additional protection for our core technologies. The market for therapeutic antibodies, vaccines and biologics is ever expanding. Securing these patents protects our innovative platform and further strengthens our position by supplementing our foundational and follow-up patents that have already been granted to Salipro Biotech in many countries, including US, EU, China and Japan."

About Salipro Biotech AB
Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.

Spotlight

Discover how Intel is collaborating with the genomics community to transform large datasets into biomedical insights that accelerate personalized care, revolutionizing how genomic workflows get executed, stored, and processed at cloud scale.For years, many aspects of life sciences work have required the fast analysis of larg datasets.


Other News
INDUSTRIAL IMPACT

WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates

WuXi Biologics | July 08, 2022

WuXi XDC, a global leading CRDMO dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug conjugates announced that a Memorandum of Understanding was signed to form a strategic partnership in AbTis' portfolio of ADC products. Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process development, ADC formulation and drug product manufacturing process development, as well as drug substance and drug product manufacturing. This full range of development and manufacturing services will be provided by WuXi XDC at facilities that are all located within a two-hour drive of each other. "We are glad to be collaborating with WuXi XDC. This partnership will allow us to leverage WuXi XDC's world-class expertise in both innovative conjugation technologies and comprehensive capabilities for ADC development and manufacturing. We look forward to making more ADC products accessible to patients." Dr. Sang Jeon Chung, CEO of AbTis "With our integrated services and know-how, we are pleased to be enabling AbTis to develop and manufacture its portfolio of ADC products," said Dr. Jimmy Li, CEO of WuXi XDC. "This strategic partnership demonstrates the trust and confidence our clients have in our end-to-end services, maintained even during the COVID-19 lockdown period, when WuXi XDC teams showcased the strong execution and reflected our commitment to a culture of 'Putting the Customer First.' We will continue to accelerate and transform the discovery, development and manufacturing of bioconjugates, enabling our global partners and benefiting patients worldwide." About AbTis AbTis is a biotechnology company that specializes in antibody-drug conjugates platform technology with its own proprietary patents and its own pipelines in developments in oncology areas. AbTis pipelines are designed to enhance the safety and efficacy of the current antibody-drug conjugates by applying AbTis linker to the mAbs. Its platform ADC linker technology is site-specific and applicable to the native antibodies, commercial antibodies, or novel antibodies under development as it requires no mutation or engineering to antibody itself. Its stable, hydrophilic and cleavable linkers can be attached to various payloads, too. Under the moto of "Patients First", AbTis has been striving to advance its ADC technology and to develop its pipelines with several other antibody and payload companies. AbTis' advanced ADC technology enables partners to co-develop pipelines together in a real open innovation setting. About WuXi XDC WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, provides end-to-end contract research, development and manufacturing of bioconjugates, including antibody drug conjugates (ADCs). The company's services cover antibodies and other biologics, chemical payloads and linkers, as well as bioconjugated drug substance and drug product. WuXi XDC has been successful in bringing multiple ADC projects to the Investigational New Drug (IND) filing stage in 15 months or less, nearly cutting in half the traditional development timeline. As of April 30, 2022, over 240 projects – from early stage to late-stage clinical – are being developed at WuXi XDC, including 26 IND-completed projects and eight projects in phase II/III.

Read More

CELL AND GENE THERAPY

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

Antengene | June 28, 2022

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma. We are delighted to partner with BeiGene, a company that strives for innovation and excellence, and is committed to developing best-in-class or first-in-class anti-cancer therapies for patients across the globe. These qualities are very similar to those of our vision at Antengene, We look forward to advancing the combination of selinexor and tislelizumab to clinical development. With good data we will be able to bring this treatment regimen to patients with T and NK-cell lymphoma, diseases that are endemic in Asia but underserved by current therapies." Dr. Jay Mei, Antengene's Founder, Chairman and CEO. Tislelizumab is a PD-1 inhibitor designed to help aid the body's immune cells to detect and fight tumors. Tislelizumab, a humanized monoclonal antibody, is specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. About T and NK-Cell Lymphoma T and NK-cell lymphoma is a set of heterogeneous diseases, accounting for 25-30% of Non-Hodgkin Lymphoma (NHL) cases in China and only about 10% in USA and Europe. There has been little improvement in the past decade when compared to B-cell Non-Hodgkin Lymphoma (B-NHL) as 5-year overall survival rate was only 30% in most common subtypes[1]. The unmet medical needs remain as agents with new mechanism of action to be explored and possibility to improve the treatment paradigm for the disease. About the SINE Compounds Selective Inhibitor of Nuclear Export (SINE) compounds are inhibitors of the major nuclear export protein Exportin 1 (XPO1). Currently, there are three oral SINE compounds, ATG-010 (selinexor), ATG-016 (eltanexor), and ATG-527 (verdinexor), under clinical development. Antengene has obtained exclusive development and commercialisation rights from Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to these three compounds in certain APAC markets.

Read More

MEDICAL

Pharmactive Enters Strategic Partnership with Nutraconnect for APAC

Pharmactive | June 08, 2022

Pharmactive Biotech Products, S.L.U., announces a new strategic partnership with Singapore-based Nutraconnect Pte, Ltd. to bring innovative, scientifically backed nutraceutical ingredients to the Asia-Pacific marketplace (not including Australia and New Zealand). The partnership will combine the strengths of both companies into a greater whole. Pharmactive will provide its well-supported, clean-label botanical extract ingredients, while Nutraconnect will function as a growth engine for the region, connecting Pharmactive with local and regional nutraceutical players seeking high-quality, pure ingredients. Nutraconnect Pte., Ltd. is a start-up led by Rohit Noronha, co-founder and Chief Growth Officer, and Nikhil Prabhakar Sawant, co-founder and CEO. Both are highly experienced leaders in the nutraceutical industry. We are very fortunate to partner with Nutraconnect, as their team possesses a great deal of market and customer information and strategic insight, allowing for quick responses to potential customers in their local time-zone, Asia is a tremendous growth-hub for Pharmactive. We already have had successes in Korea, Japan, Vietnam, and Malaysia with Affron® pure saffron extract and Aged Black Garlic [ABG+®]. Many Asian industry players, formulators, and brand owners approach us about new compounding formats or innovative product concepts to cross the nutraceutical/functional food and beverage divide. Asia is clearly the frontrunner in terms of new ingredient concepts." Jean-Marie Raymond, CEO and Founder of Pharmactive. About Pharmactive Pharmactive Biotech Products, S.L.U., is a Madrid-based pioneering biotechnology company that develops and manufactures differentiated natural ingredients supported by science, such as pure saffron extract and aged black garlic. The company's mission is to make a daily positive and significant impact on people's health and well-being through premium botanical ingredients backed by scientific studies and approved by ethics committees. Pharmactive grows, cultivates, and produces farm-to-fork botanical ingredients with a minimal ecological footprint. About Nutraconnect Founded in 2022, Nutraconnect Pte., Ltd., is a nutraceutical business growth acceleration service headquartered in Singapore. The company provides end-to-end solutions for global nutraceutical ingredient manufacturers that are looking to establish a foundation for sustainable growth in the fragmented, but booming APAC market.

Read More

INDUSTRIAL IMPACT

Angel Yeast Partners with PhaBuilder to Open PHA Factory

Angel Yeast | July 27, 2022

Angel Yeast a globally listed yeast and yeast extract manufacturer, has inked an agreement with Bejing PhaBuilder Biotechnology Co., Ltd in Yichang, Hubei province to build a large manufacturing base for polyhydroxyalkanoates (PHA) in the city. The pair will set up a joint venture company to drive the application of synthetic biology in the biotechnology industry. PHA is a polyester produced naturally by microorganisms. The biodegradable and biocompatible properties of PHA make it highly sought-after in fields such as biomedical material and biodegradable packaging material. "This collaboration with PhaBuilder marks a milestone and a significant step forward for Angel Yeast in synthetic biology. At Angel Yeast, we are very keen on innovation and exploration of new landscapes in the industry. This project is also part of our efforts to be an international and professional biotechnology company," Tao Xiong, chairman of Angel Yeast He added that the partnership is expected to forge a new venture in bioeconomy, fuel innovation in synthetic biology, and drive the expansion of the global market. Guoqiang Chen, the founder of PhaBuilder, added that by working with Angel Yeast on the initiative, major inroads have been made in converting technology breakthroughs into industrial programs for synthetic biology. "The new production line of PHA with the capacity of 30,000 tons will certainly bring more advanced technologies, new services and products for the industry and consumers. It will also create a 'greener' lifestyle. We are thrilled to see it happen," said Chen. In addition to synthetic biology, Angel Yeast has also been exploring cutting-edge development in biological agriculture. According to the company, it will be engaged in a project to produce animal feed through biological fermentation. Angel Yeast will invest some 120 million yuan to build the manufacturing center with an annual capacity of 50,000 tons. The project is estimated to start in August 2022 and to be completed in September the next year. One highlight of the project is that it uses Distillers' Dried Grains with Solubles (DDGS) as one raw material to produce yeast culture products. As a new category, yeast culture products will diversify the company's animal nutrition products lineup. About Angel Yeast Founded in 1986, Angel Yeast Co., Ltd specializes in the production of yeast and yeast derivatives. Its product range includes baker's yeast and ingredients, Chinese dim sum and seasoning, savory yeast extract, human health, animal nutrition, plant nutrition, distilled spirits and biofuels, microbial nutrition, and enzymes.

Read More

Spotlight

Discover how Intel is collaborating with the genomics community to transform large datasets into biomedical insights that accelerate personalized care, revolutionizing how genomic workflows get executed, stored, and processed at cloud scale.For years, many aspects of life sciences work have required the fast analysis of larg datasets.

Resources